Are You Living with Type 1 Diabetes? Learn About the OPTI-2 Clinical Trial for a New Mealtime Insulin Therapy. Click Here for More Info.
Are You Living with Type 1 Diabetes? Learn About the OPTI-2 Clinical Trial for a New Mealtime Insulin Therapy. Click Here for More Info.
Restoring hepatocyte metabolism to treat major metabolic disorders
Diasome’s HDV platform directly targets hepatocyte cells to restore hepatic glucose and lipid control.
Merging hepatocyte targeting with pharmaceutical treatments to address diseases impacting whole body metabolism.
01
HEPATOCYTES
Hepatocytes:
The Metabolic Control Center
At Diasome we are pioneering the science and understanding of hepatocyte cells impact on whole body metabolism to create medicines that transform human health.
These cells synchronize insulin, serotonin, and GLP-1 actions to regulate body-wide glucose and lipid levels.
01
Glucose Balance Across the Body
Hepatocytes, unique in their dual ability to both store and release glucose, rely on insulin and serotonin for balanced function. Disruptions lead to fluctuating glucose levels, causing hyperglycemia and hypoglycemia.
02
Central Role in Lipid Regulation
Acting as the chief hub for lipoprotein processes, hepatocytes manage lipid uptake, formation, and release into circulation. Common diseases like Dyslipidemia disrupt hepatocyte lipid metabolism leading to chronic conditions like NAFLD.
HDV precisely targets underlying deficiencies causing or contributing to metabolic diseases.
hepatocyte deficiency
Pancreatic Insulin
disease
Type 1 and Type 2 Diabetes
hepatocyte deficiency
Gut Serotonin
disease
Type 2 Diabetes, Dyslipidemia
hepatocyte deficiency
GLP1
disease
Type 2 Diabetes, Obesity
Hepatocyte Directed Vesicles (HDV™) Cell Targeting System delivers insulin, serotonin and GLP1 directly to specific hepatocyte receptors
01
Oral and injectable cell targeting
HDV can be customized to target drug payloads to hepatocyte cells, whether injected or taken orally.
02
Biotin is used to target the liver
HDV is designed to be accepted and removed by the liver through normal liver metabolism.
02
Safe and effective
Pristine safety profile in ~350 human exposures to date with injectable and oral dosing.
04
Diasome Pipeline
A portfolio designed to meet patient needs.
Preclinical
Oral HDV-GLP-1, Bioequivalence study
Injectable HDV-GLP-1, Novel Mechanism
Oral HDV-Serotonin, Novel Mechanism
Phase 2
Injectable HDV-Rapid Acting Insulin Open Label, MoA
Phase 2B
OPTI-2, Injectable HDV-Rapid Acting Insulin
